Last update 26 Nov 2024
Interferon alfa-2a, recombinant
Last update 26 Nov 2024
Overview
Basic Info
Drug Type Interferons |
Synonyms Interferon alfa-2a, Interferon alpha-2a, Roferon-A + [7] |
Target |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date |
RegulationOrphan Drug (US) |
Login to view timeline
Gene Sequence
Sequence Code 32821
Related
18
Clinical Trials associated with Interferon alfa-2a, recombinantRandomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis
Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’S
Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.
100 Clinical Results associated with Interferon alfa-2a, recombinant
Login to view more data
100 Translational Medicine associated with Interferon alfa-2a, recombinant
Login to view more data
100 Patents (Medical) associated with Interferon alfa-2a, recombinant
Login to view more data
1,056
Literatures (Medical) associated with Interferon alfa-2a, recombinant31 Dec 2024JOURNAL OF DERMATOLOGICAL TREATMENT
Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients
Article
Author: Zhang, Shiyu ; Liu, Yuehua ; Song, Hongbin ; Hu, Zhonghui ; Wang, Tao ; Lu, Lu ; Feng, Jindi ; Yang, Lu
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma.Objectives: This study was conducted to evaluate efficacy and safety of interferon (IFN) α-2a combined with phototherapy for early-stage MF.Methods: Thirteen patients with early-stage MF received subcutaneous injections of IFN α-2a at 3 million IU combined with phototherapy three times per week for 6 months. Treatment efficacy was measured by changes in body surface area (BSA) score and modified severity-weighted assessment tool (mSWAT) score at 1, 3, and 6 months after treatment. Histopathologic examinations of skin lesions were performed before and after treatment.Results: After 3 months of treatment, all 13 patients achieved a partial response, and BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001). After 6 months, BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001) and after 3 months (p < 0.05). Eleven patients achieved complete remission and two patients achieved a partial response (overall response rate, 100%). Histopathologic examination showed a significant decrease in the number of atypical lymphocytes in both epidermis and dermis. No severe adverse effects occurred.Conclusion: IFN α-2a in combination with phototherapy may be an effective and safe alternative modality for early-stage MF.
01 Jul 2024JOURNAL OF HEPATOLOGY
PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial
Article
Author: Zhang, Fengdi ; Liu, Yanhong ; Zhang, Yongmei ; Zhang, Xinxin ; Wu, Xiaoping ; Zhu, Haoxiang ; Guo, Yifei ; Li, Fahong ; Yu, Jie ; Li, Qingxing ; Qu, Lihong ; Chen, Liang ; Wang, Jinyu ; Zhang, Jiming ; Huang, Yuxian ; Zhang, Wenhong ; Zhang, Qiran ; Mao, Richeng ; Shen, Zhongliang ; Yang, Feifei ; Qi, Xun
BACKGROUND & AIMS:
Nucleo(s)tide analogue (NUC) cessation can lead to hepatitis B surface antigen (HBsAg) clearance but also a high rate of virological relapse. However, the effect of pegylated interferon alpha-2a (PegIFN-α-2a) on virological relapse after NUC cessation is unknown. Therefore, this study aimed to evaluate the effect of switching from NUC to PegIFN-α-2a treatment for 48 weeks on virological relapse up to week 96.
METHODS:
In this multicenter randomized-controlled clinical trial, 180 non-cirrhotic patients with HBeAg-negative chronic hepatitis B on continuous NUC therapy for ≥2.5 years, with HBV DNA levels <60 IU/ml, were randomized to discontinue NUC therapy (n = 90) or receive 48 weeks of PegIFN-α-2a treatment (n = 90). Patients were followed up for up to 96 weeks. The primary endpoint was the virological relapse rate up to week 96.
RESULTS:
Intention-to-treat analysis revealed patients in the interferon monotherapy group had significantly lower cumulative virological relapse rates than the NUC cessation group until week 96 (20.8% vs. 53.6%, p <0.0001). Consistently, a significantly lower proportion of patients in the interferon monotherapy group had virological relapse than those in the NUC cessation group at 48 weeks off treatment (17.8% vs. 36.7%, p = 0.007). The virological relapse rate positively correlated with HBsAg levels in the NUC cessation group. The interferon monotherapy group had a lower cumulative clinical relapse rate (7.8% vs. 20.9%, p = 0.008) and a higher HBsAg loss rate (21.5% vs. 9.0%, p = 0.03) than the NUC cessation group.
CONCLUSIONS:
Switching from NUC to PegIFN-α-2a treatment for 48 weeks significantly reduces virological relapse rates and leads to higher HBsAg loss rates than NUC treatment cessation alone in patients with HBeAg-negative chronic hepatitis B.
IMPACT AND IMPLICATIONS:
Nucleo(s)tide analogue (NUC) cessation can lead to HBsAg clearance but also a high rate of virological relapse, but an optimized scheme to reduce the virological relapse rate after NUC withdrawal is yet to be reported. This randomized-controlled trial investigated the effect of switching from NUC to PegIFN-α-2a treatment for 48 weeks on virological relapse up to week 96 in patients with HBeAg-negative chronic hepatitis B. The interferon monotherapy group had a significantly lower cumulative virological relapse rate (20.8% vs. 53.6%, p <0.0001) and higher HBsAg loss rate (21.5% vs. 9.0%, p = 0.03) than the NUC cessation group up to week 96. This provides an optimized strategy for NUC cessation in HBeAg-negative patients.
TRIAL REGISTRATION NUMBER:
NCT02594293.
02 Jan 2024Ocular immunology and inflammation
Cerebro-Ocular Toxocariasis Revealed by Bilateral Cystoid Macular Edema
Article
Author: Tadayoni, Ramin ; Hié, Miguel ; Touhami, Sara ; Paris, Arianna ; Bodaghi, Bahram
DESIGN:
Case Report Case description: This report describes the case of a female patient diagnosed with oculo-cerebral toxocariasis manifesting initially in the form of isolated bilateral cystoid macular edema. Diagnosis was made by means of positive anterior chamber and lumbar puncture western blots. The unusual presentation, ancillary findings and treatment are discussed. The control of intraocular inflammation that was only partially responsive to steroids was eventually achieved with pegylated interferon alfa-2a.
CONCLUSION:
Isolated macular edema is a rare presentation of ocular toxocariasis. Interferon alfa-2a may prove useful in case of insufficient control of inflammation.
100 Deals associated with Interferon alfa-2a, recombinant
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hairy Cell Leukemia | US | 03 Jun 1986 | |
| Hepatitis C | US | 03 Jun 1986 | |
| Philadelphia chromosome positive chronic myelogenous leukemia | US | 03 Jun 1986 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Renal Cell Carcinoma | Phase 3 | BG | 01 Jan 2007 | |
| Renal Cell Carcinoma | Phase 3 | RO | 01 Jan 2007 | |
| Renal Cell Carcinoma | Phase 3 | RU | 01 Jan 2007 | |
| Renal Cell Carcinoma | Phase 3 | UA | 01 Jan 2007 | |
| Renal Cell Carcinoma | Phase 3 | GB | 01 Jan 2007 | |
| Follicular Lymphoma | Phase 3 | DK | 01 Oct 2002 | |
| Follicular Lymphoma | Phase 3 | NO | 01 Oct 2002 | |
| Follicular Lymphoma | Phase 3 | SE | 01 Oct 2002 | |
| Hepatitis C, Chronic | Phase 2 | CN | 01 May 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 42 | (Polycythemia vera) | uhklgyuhzg(bqdmsfrqib) = ddlqfnxhjc yirdutpbfw (buiuscovlc ) | - | 20 May 2015 | ||
(Essential thrombocytemia) | uhklgyuhzg(bqdmsfrqib) = nyfnmcvjfg yirdutpbfw (buiuscovlc ) | ||||||
Phase 3 | 1,106 | utdpcxotgq(eaejzycqmi) = eaytusayon gvfmdipeay (dvitdlsmue, tzaigyiqyq - qpbikueisa) View more | - | 14 Oct 2013 | |||
Phase 2 | Metastatic Renal Cell Carcinoma First line | 146 | tprwnwdwaq(fuvnriqicu) = kxvcznwyqs ablrqsifzh (wibhlnwscs, 11.7 - 18.0) View more | Positive | 01 Sep 2013 | ||
Not Applicable | 23 | uqxvosrjde(edlfnylyhh) = flu-like symptoms were observed in the vast majority of the patients without necessitating interruption of the treatment ymsofmqqvu (ynlpntceuw ) View more | Positive | 12 Jun 2013 | |||
Phase 2 | 488 | Interferon Alpha+Thymosin-alpha-1+Dacarbazin (Dacarbazin + Interferon Alpha + Thymosin-alpha-1 1.6 mg) | qhqhemyiei(jqiaewkqhv) = ylubytuuix tljjeuhpvr (iwakfeetzj, neqetuglfd - iissaxxzhc) View more | - | 02 Jun 2009 | ||
Interferon Alpha+Thymosin-alpha-1+Dacarbazin (Dacarbazin + Interferon Alpha + Thymosin-alpha-1 3.2 mg) | qhqhemyiei(jqiaewkqhv) = ichvrvwaeb tljjeuhpvr (iwakfeetzj, nibbalrzkj - szcwcijzhp) View more | ||||||
Not Applicable | 53 | Interferon alpha2a | btbcheawbl(dmfcegcffn) = czvilnebsu bilistgnnz (rdiwypkdez ) View more | - | 10 Nov 2008 | ||
yyvcmitixj(mifqiexjnf) = flrzwioojj jfatcbyzln (kqhvewdjaf ) | |||||||
Not Applicable | 16 | Interferon alfa-2a 3 million IU | qzeiuactmw(ffgonfacgy) = lkmgdneizj hpfjjwyhet (wkqjjlfkln ) View more | - | 11 Jun 2008 | ||
Interferon alfa-2a 4.5 million IU | qzeiuactmw(ffgonfacgy) = zcgydffpkc hpfjjwyhet (wkqjjlfkln ) | ||||||
Not Applicable | 41 | vzflvbouxd(xiyimhpina) = xkjrtrahof qedqbqzmcr (fpcgwyuxmp ) | Positive | 17 Oct 2005 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free